Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $27,167.40 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Nadia Waheed sold 3,510 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $7.74, for a total value of $27,167.40. Following the completion of the transaction, the insider directly owned 314,907 shares in the company, valued at approximately $2,437,380.18. This represents a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Nadia Waheed also recently made the following trade(s):

• On Thursday, February 12th, Nadia Waheed sold 7,863 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.04, for a total transaction of $71,081.52.

Ocular Therapeutix Stock Up 0.9%

Shares of NASDAQ OCUL opened at $9.59 on Friday. The company’s 50 day moving average price is $10.38 and its 200-day moving average price is $11.59. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44. The company has a market capitalization of $2.09 billion, a P/E ratio of -6.66 and a beta of 0.90.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. The company had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. Ocular Therapeutix’s revenue for the quarter was down 22.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.29) earnings per share. Equities analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Trending Headlines about Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard Lindstrom bought 60,229 shares at ~ $7.66, increasing his stake ~32% — a notable insider purchase that signals confidence and provides direct demand support. SEC Filing – Lindstrom Form 4
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the Macula Society meeting and host investor events — favorable readouts or constructive management commentary could be a major catalyst for the stock and offset recent weakness. SOL‑1 Presentation
• Positive Sentiment: Large institutional holders have been adding to positions (Vanguard, Avoro, TCG Crossover, Adage, Geode), which supports longer‑term demand even amid short‑term volatility. MarketBeat Institutional Summary
• Neutral Sentiment: Analyst coverage remains mixed-to-positive overall (consensus “Moderate Buy,” average target ~$23.78) — this keeps a bullish case intact but creates a wide range of expectations that earnings or SOL‑1 commentary could swing stock directionally. MarketBeat Summary
• Neutral Sentiment: Smaller, individual insider sales (e.g., Nadia Waheed sold 3,510 shares at ~$7.74) appear modest relative to major holdings and are unlikely alone to change long‑term conviction. SEC Filing – Waheed Form 4
• Negative Sentiment: Several executives/directors sold shares on Feb. 23 (Sanjay Nayak, Jeffrey Heier, Peter Kaiser and Pravin Dugel — Dugel sold 20,056 shares) at roughly $8.28; clustered insider selling increases available float and weighs on near‑term sentiment. SEC Filing – Dugel Form 4
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (~6.9% of the float), elevating bearish pressure and the potential for sharper downside or volatile moves ahead of catalysts. (Days‑to‑cover ~3.0.)
• Negative Sentiment: Needham trimmed its price target to $18 (from $20), a downgrade that could temper enthusiasm among some growth/biotech investors despite other higher targets. Needham Price Target Cut

Hedge Funds Weigh In On Ocular Therapeutix

Several large investors have recently bought and sold shares of OCUL. Steward Partners Investment Advisory LLC grew its stake in shares of Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares in the last quarter. Hilton Head Capital Partners LLC bought a new position in shares of Ocular Therapeutix during the fourth quarter valued at about $42,000. Nisa Investment Advisors LLC boosted its holdings in Ocular Therapeutix by 62.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,392 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new stake in shares of Ocular Therapeutix during the fourth quarter valued at approximately $61,000. Finally, State of Wyoming bought a new stake in Ocular Therapeutix during the fourth quarter worth $78,000. 59.21% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on OCUL. HC Wainwright raised their target price on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday, February 17th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, February 5th. Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Finally, Needham & Company LLC cut their target price on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.78.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.